GlaxoSmithKline spinout SR One strikes $500m hard cap for debut independent fundraise

• Mike Didymus
• November 23, 2020

Transatlantic biotech investor SR One has raised its first fund in the wake of spinning out from pharmaceutical giant GlaxoSmithKline.